Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

  • Home
  • 2020
  • May
  • 13
  • Bristol Myers Squibb and bluebird bio to Present Updated Positive Results from Pivotal KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma Patients at ASCO20

Original Source

On May 13, 2020

Post navigation

Previous PostBristol Myers Squibb and bluebird bio Provide Regulatory Update on Idecabtagene Vicleucel (ide-cel, bb2121) for the Treatment of Patients with Multiple Myeloma
Next PostU.S. Food and Drug Administration Approves Bristol Myers Squibb’s Pomalyst® (pomalidomide) for AIDS-Related and HIV-Negative Kaposi Sarcoma

Related Post

May 25, 2022
  • Business News

Boeing, NASA Complete First Starliner Space Station Flight Test

May 25, 2022
  • Business News

Northrop Grumman Australia Announces Tech Showcase Winners

May 25, 2022
  • Business News

IQVIA CFO Ron Bruehlman to Speak at Jefferies Healthcare Conference on June 10, 2022

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219